Beat-AML 2024 ELN-Refined Risk Stratification for Older Adults with Newly Diagnosed AML Given Lower-Intensity Therapy

By sjmartinez • August 8, 2024

Hoff FW, Blum W, Huang Y, Welkie RL, Swords R, Traer E, Stein EM, Lin TL, Archer KJ, Patel PA, Collins RH Jr, Baer MR, Duong VH, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics TJ, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran E, Koenig KL, Heerema NA, Chen TL, Martycz M, Stefanos M, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate U, Mims AS, Byrd JC, Madanat YF. Beat-AML 2024 ELN-Refined Risk Stratification for Older Adults with Newly Diagnosed AML Given Lower-Intensity Therapy. Blood Adv. 2024 Aug 7:bloodadvances.2024013685. doi: 10.1182/bloodadvances.2024013685. Epub ahead of print. PMID: 39110987.

Tags: Hematology/Oncology, Publications

Achieving timely treatment for early-stage non-small cell lung cancer: Factors associated with delayed surgical resection and proposed quality benchmarks

Tupper HI, Bhattacharjee J, Sarovar V, Amara D, Schmittdiel JA, Quesenberry CP, Cummings AL, Velotta JB, Sakoda LC. Achieving timely treatment for early-stage non-small cell[...]

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial

Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, O'Reilly EM, Wainberg ZA, Bullock A. Impact of UGT1A1*28polymorphism in[...]

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

Socinski MA, Stahel R, Lee DH, Cappuzzo F, Nishio M, Lovly CM, Ozyilkan O, Li Q, Johnson M, Garon EB, Kilickap S, Ferreira da Silva[...]